Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Raw Materials (2023 - 2025)

Cytosorbents (CTSO) has disclosed Raw Materials for 3 consecutive years, with $565000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Raw Materials changed N/A year-over-year to $565000.0, compared with a TTM value of $565000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $570000.0, down 16.89% over the prior year.
  • Raw Materials was $565000.0 for Q3 2025 at Cytosorbents, up from $491000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $685801.0 in Q4 2023 and bottomed at $491000.0 in Q2 2025.
  • Average Raw Materials over 3 years is $571721.2, with a median of $565000.0 recorded in 2025.
  • Peak annual rise in Raw Materials hit 16.89% in 2024, while the deepest fall reached 16.89% in 2024.
  • Year by year, Raw Materials stood at $685801.0 in 2023, then dropped by 16.89% to $570000.0 in 2024, then dropped by 0.88% to $565000.0 in 2025.
  • Business Quant data shows Raw Materials for CTSO at $565000.0 in Q3 2025, $491000.0 in Q2 2025, and $546805.0 in Q1 2025.